戻る Agenda
Session 6: Joint Clinical Assessment (REA)
Session Chair(s)
Claudine Sapède, PHARMD
Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland
In this session panellists will discuss the state of play, experience from REA pilots and potential development post 2020 surrounding joint clinical assessments (JCAs) - a key component of the joint work across European HTA agencies. What good quality means for stakeholders in relation to clinical HTA methodological standards for JCAs? What practical as well as policy implications this may have for stakeholders and sustainability of EU cooperation? During the workshop session the audience will also be invited to share its perspective and experience.
Speaker(s)
Panel Discussion
Anja Schiel, PHD
Norwegian Medical Products Agency (NOMA), Norway
Special Advisor, Lead Methodologist/Statistician; NOMA
Panel Discussion
Edith Frénoy, MA, MSC
MSD Europe Inc., Belgium
Director, European Public Policy – Strategic EU Advocacy Lead
Panel Discussion
Michael Berntgen, PHD
European Medicines Agency, Netherlands
Head of Scientific Evidence Generation
Panel Discussion
Anne Willemsen, MSC
ZIN - National Health Care Institute, Netherlands
Senior Project Manager, Joint Production Co-Lead Partner - Pharmaceuticals
Kalitsa Filioussi
ORE, Novartis Oncology, Italy
European Market Access Director, Hematology